AstraZeneca’s trial flop raises bigger questions around its pipeline
AstraZeneca‘s failed late-stage lawsuit against Wainua was never expected to have a major financial impact on the company.
Most analysts estimate that trial misses are only erased from valuation models by 2-4%. But shares lost roughly twice as much value in a single session; This suggests that the market reaction reflects more than the loss of a drug intended to treat a rare heart disease.
That disconnect has turned the spotlight away from Wainua itself and onto something harder to measure: whether the valuation premium investors have long assigned to one of Europe’s most respected pharmaceutical pipelines is justified.
AstraZeneca has for years been among the richest valuations among Europe’s big pharmaceutical companies, assuming management consistently delivers successful late-stage clinical trials in oncology, rare diseases and specialty drugs and fills its portfolio with blockbuster new drugs.
During CEO Pascal Soriot’s 14-year reign, AstraZeneca gained a reputation as a pharmaceutical giant that rarely published negative trial results.
Wainua was not expected to be one of AstraZeneca’s biggest products. Instead, the surprise lay in the failure of a program that many investors saw as having a high probability of success.
Analysts mostly say the disappointment hasn’t undermined AstraZeneca’s long-term growth story, but may have raised the bar for proving it.
The issue goes beyond the extra revenue Wainua would add to AstraZeneca’s top line because it undermines the company’s credibility, Jefferies analysts wrote in a note to clients on Thursday.
“This was supposed to be a slam dunk that made the outright failure surprising.”
Bigger than a drug
The financial impact of Wainua’s failure to treat ATTR cardiomyopathy, a rare and life-threatening heart condition, appears relatively modest.
Citi estimates the net present value impact at roughly 3%. Jefferies is forecasting around 2%, and Leerink Partners’ price target cut suggests a similarly limited hit. Bank of America described the sales impact as “mid-single digits,” while Morningstar said reduced sales estimates for Wainua did not materially change the company’s valuation.
These predictions contrast with the market’s reaction, as shares fell 6.2% in Thursday’s session, the stock’s worst day in two years, falling an additional 3% on Friday.
An AstraZeneca spokesman declined to comment further on the share price reaction.
Rather than stripping some of Wainua’s sales from its models, investors may be re-evaluating their confidence in AstraZeneca’s broader product line and application.
Dan Coatsworth, market manager at AJ Bell, said AstraZeneca has taken more hits than losses recently, creating high expectations for success.
“AstraZeneca has bold plans to reach $80 billion in sales by 2030, and investors will now ask whether that target is credible,” Coatsworth said in emailed comments.
While Jefferies said the failed trial does not threaten management’s 2030 target, Citi continues to expect the company can exceed that target.
After speaking with management, Leerink noted that Wainua’s removal for ATTR-cardiomyopathy reduces headroom from the company’s consensus of approximately $82.7 billion to approximately $80.8 billion, reflecting $1.9 billion of Wainua revenues in 2030.
Morningstar left its fair value estimate unchanged, saying the downturn “does not change our view on late-stage drug development capabilities” and noted that AstraZeneca’s oncology franchise, rare disease business and broader product pipeline remain intact.
Both Goldman Sachs and Bank of America emphasized that investors did not seriously consider the possibility that the case would fail. of Alnylam rival drug Amvuttra, which works similarly.
Is the margin of error decreasing?
The failed study also coincides with an important period for AstraZeneca.
Many of the company’s biggest catalysts, including the AVANZAR trial for lung cancer, SERENA-4 for breast cancer and cliramitug for ATTR cardiomyopathy, are expected to report data in the coming months, meaning investors’ attention is now focused on fewer high-profile reads.
AstraZeneca’s shares listed in London in the last 12 months.
“All eyes are on AVANZAR,” Jefferies wrote, describing it as the next big catalyst that will define sentiment. The announcement is expected to be made in July or August.
Leerink suggested that this downturn puts even greater focus on the remaining “dual events” expected later this year.
Most analysts continue to recommend buying the stock. Citi reiterated AstraZeneca as Europe’s top drug pick, Bank of America reiterated its Buy rating and Jefferies argued investors should “buy the dip.”
